TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA

Key Takeaways TVTX shares fell after the FDA extended the Filspari sNDA review for FSGS by three months.The delay followed an amendment request, with no new safety or manufacturing data required by FDA.Filspari could become the first FDA-approved FSGS therapy, with Travere Therapeutics continuing launch prep.Shares of Travere Therapeutics (TVTX) were down 14.6% on Tuesday after the company announced that the FDA had extended the review timeline for the supplemental new drug application (sNDA) seeking label ...